Eisbach Bio GmbH. (7/18/24). "Press Release: Eisbach to Advance Training in Metabolic Regulation of Genome Function as Part of the EU-funded Research Network NUCLEAR". Munich.

	Region	Europe
	Product	oncology
	Product 2	business development (state/region)

Eisbach Bio GmbH is set to train the next generation of scientists in the metabolic regulation of genome function through the innovative project NUCLEAR. Coordinated by the Josep Carreras Leukaemia Research Institute near Barcelona, Spain, this network will guide 17 doctoral candidates to become world-class experts and provide new insights at the interface of metabolism and genome regulation, a topic highly relevant to stem cell biology, obesity and cancer. This project is a Marie Sklodowska Curie Action Doctoral Network funded by the European Commission under the Horizon Europe framework program.

Metabolism is not only a consequence of cell identity, but plays an active role in cell-fate decisions and human disease. By altering chromatin structure, cellular metabolism influences gene expression, impacting both stem and cancer cells. Eisbach will investigate new paradigms of metabolism–chromatin interaction and translate this knowledge into novel targets for cancer treatment.

Given the interdisciplinary nature of this emerging field, NUCLEAR will unite European leaders in metabolomics, functional genomics, chromatin regulation, stem cell biology and cancer. Innovators in precision biology, nutrition, ‘omics and drug R&D, including Eisbach Bio GmbH, complement the network’s broad research, training, education and translation.

NUCLEAR’s core aim is to develop a generation of creative, entrepreneurial and innovative researchers. Our science graduates will translate their knowledge into novel therapies and generate great value for society, ensuring the project’s long-term impact on biomedicine.

As core partner, Eisbach Bio GmbH looks forward to this pioneering research and training PhD candidates at the following leading institutions will drive our research innovation:

Josep Carreras Leukaemia Research Institute (Spain)
Universitetet i Bergen (Norway)
University of Milan (Italy)
Leibniz-Institut für Analytische Wissenschaften (Germany)
Max Delbrück Zentrum (Germany)
Universitetet i Tromsø – Norges Arktiske Universitet (Norway)
University of Copenhagen (Denmark)
Universitair Medisch Centrum Utrecht (Netherlands)
Stichting Radboud University (Netherlands)
Centre for Genomic Regulation (Spain)
Karolinska Institutet (Sweden)
University of Cyprus (Cyprus)
King Abdullah University of Science and Technology (Saudi Arabia)
The Babraham Institute (United Kingdom)
And the industrial partners Eisbach Bio GmbH and Precision for Health (Spain)

Further support for the PhD training program comes from Thermo Fisher Scientific (Bremen) GmbH, Stichting SciLink (SciLink), Asociación Española Contra el Cáncer (AECC), Ludwig-Maximilians-Universität München (LMU), Universitat Autònoma de Barcelona (UAB), Universität Duisburg-Essen (UDE), University of Cambridge (CU), Universidad Autónoma de Madrid (UAM), Charité Universitätsmedizin Berlin (CUB), Universitat Pompeu Fabra (UPF), Instituto Europeo di Oncologia SRL (EIO), and Universiteit Utrecht (UU).

This project has received funding from the European Union’s Horizon Europe research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 101166838.

Eisbach Bio GmbH is excited to be part of this cutting-edge initiative and looks forward to advancing the field of metabolic regulation of genome function.

About Eisbach Bio GmbH

Eisbach Bio GmbH is a LMU spin off established in January 2019 on the Großhadern-Martinsried campus. Eisbach exploits the innovative therapeutic concept of synthetic lethality in tumor cells and develops small molecule inhibitors for the personalized therapy of cancer in genetically defined patient groups, including for indications with no therapeutic options. Cancer genomics has revealed tumor-specific genes that cancer cells critically depend on for survival. By targeting these molecular vulnerabilities, Eisbach’s inhibitors hit the Achilles heel of tumors, effectively eliminating cancer cells with minimal side effects, while healthy cells remain largely unharmed. Eisbach has developed a proprietary screening and development platform that specifically identifies allosteric inhibitors of these tumor-essential molecular machines, generating efficacious drugs with limited toxicity.

More information:

Eisbach Bio GmbH:

www.eisbach.bio
Email: mediarelations@eisbach.bio

The NUCLEAR Project:

nuclear@carrerasresearch.org

Record changed: 2025-05-18

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com